Overview

Alois Alzheimer (14 June 1864 – 19 December 1915) was a German psychiatrist and neuropathologist whose clinical and laboratory observations in the early 20th century established the basis for what is now called Alzheimer's disease. He combined careful bedside description with microscopic examination of brain tissue to link symptoms of progressive cognitive decline with reproducible pathological changes.

Early clinical work and the case of Auguste Deter

On 25 November 1901 Alzheimer began caring for Auguste Deter, a woman in her early fifties who showed rapid deterioration of memory, disorientation, language disturbance and marked fluctuations in mood and behavior. Her husband had brought her to a psychiatric clinic because she could no longer manage ordinary household tasks and at times was markedly suspicious and confused. Alzheimer recorded her symptoms in detail and, after her death in 1906, performed a neuropathological examination of her brain. The combination of an unusual clinical picture for a relatively young patient and distinctive tissue changes made the case notable among contemporaries.

Neuropathological findings

In examinations of affected brains Alzheimer reported two kinds of lesions that later became central to the diagnosis of the disorder: extracellular, protein-rich deposits now known as amyloid plaques, and abnormal fibrous inclusions within neurons called neurofibrillary tangles. Subsequent research has identified major molecular constituents of these lesions, including beta-amyloid in plaques and tau protein in tangles, and has developed staining and imaging methods to detect them. Alzheimer’s approach — correlating clinical course with postmortem examination — set a methodological standard in neuropathology.

Reception and the eponym

Alzheimer presented his findings to colleagues and published case descriptions that attracted the attention of contemporaries. Emil Kraepelin, a leading psychiatrist and classifier of mental disorders, recognized the significance of Alzheimer’s reports and used the name "Alzheimer's disease" in his influential clinical handbook to denote the presenile form of the condition. Over time the eponym came to be applied more broadly to the common neurodegenerative syndrome of progressive memory and cognitive impairment in older adults.

Career and later life

Alzheimer worked in several psychiatric clinics and pathology laboratories in Germany, where he pursued both clinical psychiatry and microscopic studies of brain tissue. His work took place during a period when neuropathology and psychiatry were developing closer ties, and his combination of clinical observation with histological technique exemplified the evolving scientific approach to brain disease. He continued his research until his death in 1915.

Legacy and modern significance

The identification of consistent lesions in affected brains shifted research toward biological causes of dementia and inspired decades of study into mechanisms, diagnostics and potential therapies. Today, Alzheimer's disease is a leading cause of cognitive impairment in older adults and a major focus of neuroscience, neurology and public health. Modern work has elaborated genetic risk factors (including well-known risk alleles), molecular pathways involving beta-amyloid and tau, and imaging and fluid biomarkers used in research and clinical practice.

Context and further reading

While the eponym honors Alzheimer’s pioneering observations, the study of dementia encompasses a range of disorders with diverse causes. For a broader perspective on mental health disciplines and clinical practice see materials on psychiatry. For summaries of disease mechanisms, diagnosis and current research directions consult resources focused on Alzheimer's disease and related neurodegenerative conditions.

Notable points

  • Alzheimer’s original case, commonly referenced by the patient’s surname Auguste Deter, exemplified a presenile presentation that drew attention to pathological differences from ordinary senility.
  • His work illustrated the value of clinicopathological correlation — matching clinical symptoms with anatomical findings — in understanding brain disease.
  • Research since Alzheimer’s time has expanded knowledge of molecular pathology, risk factors and diagnostic tools, but many clinical and therapeutic challenges remain.